StockData
Foghorn Therapeutics Inc. logo

Foghorn Therapeutics Inc. (FHTX) company profile

FHTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/30
$1.79−0.28 (-13.53%)

Close on Nov 16, 2026Market cap $106.30MP/E –Yield –

About Foghorn Therapeutics

Pharmaceutical Preparations, SIC 2834

Foghorn is a clinical-stage biotechnology enterprise that develops precision therapeutics designed to treat serious diseases, primarily cancers. The company targets the chromatin regulatory system to correct aberrant gene expression orchestrating disease progression. Leveraging its proprietary Gene Traffic Control platform, Foghorn identifies genetically determined dependencies within diseased cells to discover and design small molecule drug candidates, such as enzymatic inhibitors, targeted protein degraders, and transcription factor disruptors. Its lead candidate, FHD-909, is an orally administered selective SMARCA2 inhibitor undergoing Phase 1 clinical testing for non-small cell lung cancer and solid tumors in collaboration with Eli Lilly and Company.

The company advances multiple preclinical and clinical programs across several oncology targets, including SMARCA2, CBP, EP300, and ARID1B. Foghorn conducts its operations with a workforce of 106 employees as of late 2025. It maintains collaborative research, development, and commercialization agreements covering the United States market. The provided text does not disclose the location of the company's headquarters or other geographic facilities.

Summary of the business section of Foghorn Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Foghorn Therapeutics Inc.
Headquarters
Cambridge, MA
Address
500 Technology Square, Suite 700 02139
Phone
(617) 586-3100
Employees
106, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte& Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
FHTX
Exchange
Nasdaq
IPO date
Oct 23, 2020
Shares outstanding
59M, Jul 31, 2026
Public float
$172.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1822462
CUSIP
344174107
ISIN
US3441741077
FIGI
BBG00HFZPB88
Share class FIGI
BBG00HFZPB97
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Adrian GottschalkChief Executive Officer, Director511,704
Ryan D. MaynardChief Financial Officer–
Anna RivkinChief Business Officer–
Michael LaCasciaChief Legal Officer–
Carlos CostaChief People Officer0
Alfonso Quintas CardamaChief Medical Officer–
Steven F. BellonChief Scientific Officer151,957
Kristian HumerChief Financial Officer–
Thomas J. Lynch Jr.Director–
Scott BillerDirector–
Michael MendelsohnDirector–
Neil GallagherDirector–
Stuart DutyDirector–
Simba GillDirector34,061
Ian F. SmithDirector72,072
B. Lynne ParshallDirector–
Douglas G. ColeDirector–
Flagship Ventures Fund V, L.P.Director–
Noubar AfeyanDirector–
Ventures Fund V. General Partner LLC FlagshipDirector–
Flagship Pioneering, LLCDirector–
Ventures Opportunities Fund I. General Partner LLC FlagshipDirector9,330,878
Flagship Pioneering Special Opportunities Fund II, L.P.Director–
Flagship Ventures Opportunities Fund I, L.P.Director–
Pioneering Special Opportunities Fund II General Partner LLC FlagshipDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$2.36M$3.07M$1.17M$84–
FY2024$1.56M$2.38M$1.68M$73–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Adrian Gottschalk
President and Chief Executive Officer
$638.00K$1.33M$385.99K$3.00K$2.36M+51%
Steven Bellon
Chief Science Officer
$505.00K$469.26K$222.20K$3.00K$1.20M+33%
Alfonso Quintás-Cardama
Chief Medical Officer
$494.00K$419.61K$217.36K$3.00K$1.13M+47%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Oct 23, 2020
Offer price
$16.00
Securities offered
7,500,000
Gross proceeds
$120.00M
Exchange
Nasdaq
First trading day
Oct 23, 2020
First-day close
$18.12+13.3%
Lock-up ends (est.)
Apr 21, 2021

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 106 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?